浆液性视网膜脱离的糖尿病黄斑水肿患者接受雷珠单抗治疗后的功能与解剖结局
本回顾性研究纳入78只眼(浆液性视网膜脱离组39只、无浆液性视网膜脱离组39只,按基线最佳矫正视力匹配),评估雷珠单抗治疗糖尿病黄斑水肿时浆液性视网膜脱离对功能和解剖结局的影响。结果显示两组第12个月最佳矫正视力平均变化无统计学差异,浆液性视网膜脱离组中央视网膜厚度下降幅度更大,注射次数无差异。
要点
- 两组第12个月最佳矫正视力平均变化无统计学差异(11±12个字母 vs 12±13个字母,P=0.78)。
- 浆液性视网膜脱离组中央视网膜厚度平均变化为-235±170μm,无浆液性视网膜脱离组为-130±96μm(P=0.013)。
- 两组注射次数无统计学差异(5.2次 vs 5.5次,P=0.46)。
核心结论
- 无论是否存在浆液性视网膜脱离,雷珠单抗治疗后最佳矫正视力获得相似。
- 作者认为,糖尿病黄斑水肿伴浆液性视网膜脱离时通常观察到的较高视力获益可能与较低的基线最佳矫正视力相关。
研究设计与样本
- 回顾性研究,连续纳入接受雷珠单抗治疗的浆液性视网膜脱离患者;每例浆液性视网膜脱离患者随机匹配一例基线最佳矫正视力相同的无浆液性视网膜脱离患者。
- 共纳入78只眼,浆液性视网膜脱离组(G1)39只,无浆液性视网膜脱离组(G2)39只。
- 主要终点为基线至第12个月最佳矫正视力的平均变化。
主要发现
- 基线最佳矫正视力两组相似(45.2个字母和45.3个字母)。
- 基线至第12个月最佳矫正视力平均变化无统计学差异:G1为11±12个字母,G2为12±13个字母(P=0.78)。
- 基线中央视网膜厚度G1为650±130μm,G2为480±79μm;平均变化G1为-235±170μm,G2为-130±96μm(P=0.013)。
- G1和G2分别接受5.2次和5.5次注射(P=0.46)。
- G1中38.5%的患者视力获得≥15个字母、2.6%丧失≥15个字母,G2分别为41%(P=0.1)和5.1%(P=0.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the effect of serous retinal detachment (SRD) on functional and anatomical outcomes in ranibizumab-treated patients with diabetic macular edema (DME). METHODS: All consecutive ranibizumab-treated patients with SRD were included in this retrospective study. For each patient with SRD, a patient without SRD with the same baseline best-corrected visual acuity (BCVA) was randomly included for adjustment on their baseline BCVA. All patients with SRD were included in group 1 (G1) and those without SRD in G2. The primary endpoint was the mean change in BCVA between baseline and month 12 (M12). Secondary endpoints were the mean change in central retinal thickness (CRT) between baseline and M12, injection number, and proportion of patients who gained/lost ≥15 letters. RESULTS: Seventy-eight eyes were included, 39 in each group. Baseline BCVA was similar in both groups (45.2 and 45.3 letters). Mean change in BCVA between baseline and M12 was not statistically different: 11 ± 12 letters in G1 and 12 ± 13 letters in G2 (P = 0.78). Baseline CRT was 650 ± 130 μm in G1 and 480 ± 79 μm in G2. Mean change in CRT was -235 ± 170 μm in G1 and -130 ± 96 μm in G2 (P = 0.013). Patients received 5.2 and 5.5 injections in G1 and G2 (P = 0.46). In group 1, 38.5% and 2.6% of patients respectively gained and lost ≥15 letters versus 41% (P = 0.1) and 5.1% (P = 0.1) in G2. CONCLUSIONS: Similar BCVA gains were observed regardless of the presence of SRD. The higher visual gain usually observed in DME with SRD could be associated with a lower baseline BCVA.
引用
- Giocanti-Aurégan A, Hrarat L, Qu LM, et al. Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab. Invest Ophthalmol Vis Sci. 2017. PMID: 28152140. doi:10.1167/iovs.16-20855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。